J P Morgan Chase & Co reissued their neutral rating on shares of Smith & Nephew plc (LON:SN) in a report released on Monday, November 6th, MarketBeat.com reports. J P Morgan Chase & Co currently has a GBX 1,382 ($18.18) price target on the stock.
Several other research analysts have also recently commented on SN. reissued a hold rating and set a GBX 1,320 ($17.36) target price on shares of Smith & Nephew in a research note on Monday, July 10th. Deutsche Bank AG boosted their target price on Smith & Nephew from GBX 1,200 ($15.78) to GBX 1,315 ($17.30) and gave the stock a hold rating in a research note on Monday, October 23rd. Credit Suisse Group reaffirmed a neutral rating and set a GBX 1,280 ($16.84) price target on shares of Smith & Nephew in a report on Friday, July 28th. Jefferies Group LLC boosted their target price on Smith & Nephew from GBX 1,350 ($17.76) to GBX 1,515 ($19.93) and gave the company a buy rating in a report on Friday, July 28th. Finally, Citigroup Inc. restated a sell rating and issued a GBX 1,160 ($15.26) price target on shares of Smith & Nephew in a report on Thursday, October 12th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating and two have given a buy rating to the company. The stock has an average rating of Hold and a consensus price target of GBX 1,315.82 ($17.31).
Smith & Nephew (LON SN) traded down GBX 14 ($0.18) during midday trading on Monday, hitting GBX 1,319 ($17.35). The stock had a trading volume of 1,560,159 shares, compared to its average volume of 3,220,000. Smith & Nephew has a 1-year low of GBX 1,084 ($14.26) and a 1-year high of GBX 1,442 ($18.97).
Smith & Nephew plc is a medical technology company. The Company is engaged in developing, manufacturing, marketing and selling medical devices and services. Its products and services include Sports Medicine Joint Repair, Arthroscopic Enabling Technologies (AET), Trauma & Extremities, Other Surgical Businesses, Knee Implants, Hip Implants, Advanced Wound Care, Advanced Wound Bioactives and Advanced Wound Devices.
Receive News & Ratings for Smith & Nephew plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew plc and related companies with our FREE daily email newsletter.